ストックスクリーナーアプリを入手
271.68
0.03%
-0.1502
前日終値:
$271.83
開ける：
$272.66
24時間の取引高:
719.68K
Relative Volume:
0.40
時価総額：
$52.86B
収益：
$328.68B
当期純損益:
$2.55B
株価収益率:
20.84
EPS:
13.0349
ネットキャッシュフロー:
$1.56B
1週間 パフォーマンス:
-3.44%
1か月 パフォーマンス:
-1.15%
6か月 パフォーマンス:
-20.08%
1年 パフォーマンス:
-7.46%
1日の値動き範囲:
$269.30
$274.12
1週間の範囲:
$269.30
$282.51
52週間の値動き範囲:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Compare COR vs MCK, CAH, HSIC, AHG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
271.67 | 52.89B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
747.61 | 87.88B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
223.69 | 51.94B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
79.19 | 9.10B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.26 | 1.15B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-06-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | 再開されました | Mizuho | Outperform |
| 2024-09-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-02-26 | 開始されました | Leerink Partners | Outperform |
| 2024-01-03 | 開始されました | Barclays | Overweight |
| 2023-12-14 | 開始されました | Wells Fargo | Equal Weight |
| 2023-03-31 | 開始されました | Citigroup | Buy |
| 2023-01-31 | 再開されました | Evercore ISI | Outperform |
| 2022-10-11 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-11 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-05-26 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-04-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2021-03-12 | 再開されました | Evercore ISI | In-line |
| 2021-02-04 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-02-02 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-01-06 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-01-06 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | 開始されました | Mizuho | Neutral |
| 2020-08-06 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | 開始されました | Barclays | Underweight |
| 2020-06-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | 再開されました | Credit Suisse | Outperform |
| 2020-04-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-11 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | 開始されました | Deutsche Bank | Hold |
| 2019-07-10 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | 開始されました | Guggenheim | Buy |
| 2019-04-10 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-02-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-01-17 | 開始されました | UBS | Buy |
| 2018-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2018-10-26 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | 開始されました | Berenberg | Buy |
| 2018-07-17 | 再開されました | Stifel | Hold |
| 2018-04-09 | 開始されました | MoffettNathanson | Buy |
| 2018-03-12 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | 開始されました | JP Morgan | Neutral |
| 2017-09-22 | 開始されました | William Blair | Outperform |
すべてを表示
Cencora Inc (COR) 最新ニュース
Pharmagen from Cencora Inc.specialty generics with a hospital focus - AD HOC NEWS
Are Wall Street analysts bullish on Cencora stock? - MSN
Why Centene’s Wellcare Medicare Advantage plans matter for seniors - AD HOC NEWS
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell? - TradingView
Why Cencora’s Fusion Center keeps specialty drugs flowing quietly in the background - AD HOC NEWS
Cencora Launches Enhanced Nucleus Solution for Specialty Practices - Yahoo Finance
Cencora Inc (COR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cencora Inc (COR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cencora Inc (COR) Institutional Confidence - TradingKey
Cencora Inc (COR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cencora Inc (COR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cencora Inc (COR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cencora Inc (COR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices - Business Wire
Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative - simplywall.st
Deals tracker: Baptist Health acquires Arkansas hospital - Modern Healthcare
Cencora Connect Pro platform launches to streamline specialty drug distribution - AD HOC NEWS
Cencora Inc (COR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cencora, Inc. (COR) Announces Executive Leadership Transition - GuruFocus
Cencora (COR) Announces Executive Transition in Human Resources - GuruFocus
Eva Boratto resigns from UPS board following appointment at Cencora By Investing.com - Investing.com Australia
Eva Boratto resigns from UPS board following appointment at Cencora - Investing.com
Cencora (NYSE: COR) taps Samantha Hammock as new Chief HR Officer - Stock Titan
Flagship logistics upgrade: Cencora’s Fusion Center platform scales real-time pharma visibility - AD HOC NEWS
Cencora, Inc. (COR) Stock Analysis: Exploring a 24% Potential Upside in Healthcare Distribution - DirectorsTalk Interviews
Is Cencora stock underperforming the Nasdaq? - MSN
Cencora Inc. Stock (US15135B1017): Valuation metrics in focus after steady share price climb - AD HOC NEWS
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Cencora Inc Stock (US03073E1055): Analyst Rating In Focus After Barclays Cuts Target - AD HOC NEWS
The Profit Margin Climb Cencora Stock Bears Keep Missing - Trefis
Cencora Drug Distribution Story Gains Healthcare Market Attention - Kalkine Media
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential - Yahoo Finance
Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating - marketscreener.com
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Central Garden & Pet stock (US15135B1017): earnings momentum and pet-care demand in focus - AD HOC NEWS
What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders - simplywall.st
Cencora hits 52-week low after guidance cut - MSN
Is Cencora Stock Underperforming the Nasdaq? - Yahoo Finance
Cencora, Inc. (COR) Stock Analysis: Strong Buy Ratings and 29.74% Potential Upside Spark Investor Interest - DirectorsTalk Interviews
A Look At Cencora (COR) Valuation After 2026 Guidance Update And New CAR T Distribution Deal - simplywall.st
Cencora shares fall 2% on second quarter earnings miss - Investing.com
Cencora's Specialty Supply Chain: Where COR's Growth Is Headed - Yahoo Finance
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know - Yahoo Finance
Cencora Q2 FY2026 slides: strategic moves amid revenue miss - Investing.com
Earnings Flash (COR) Cencora, Inc. Reports Q2 Revenue $78.36B, vs. FactSet Est of $81.09B - marketscreener.com
Earnings Flash (COR) Cencora, Inc. Posts Q2 Adjusted EPS $4.75 per Share, vs. FactSet Est of $4.82 - marketscreener.com
Cencora shares fall 2% on second quarter earnings miss By Investing.com - Investing.com Nigeria
Cencora Inc (COR) 財務データ
収益
当期純利益
現金流量
EPS
0.72%
0.44%
大文字化:
|
ボリューム (24 時間):